PTEROSTILBENE - Inhibe el cáncer de mama

El cáncer de mama es la segunda causa de muerte en mujeres en Chile, después del cáncer de vía biliar. La incidencia (número de casos nuevos diagnosticados) se estima en alrededor de 30 casos por cada 100.000 mujeres. A esto se agrega que por cada 100 mujeres diagnosticadas con esta enfermedad, habrá 1 hombre afectado. Por lo tanto, se estima que 1 de cada 12 a 14 mujeres desarrollarán un cáncer de mama a lo largo de su vida.

Pterostilbene treatment inhibits the growth of breast cancer in vitro through caspase dependent apoptosis. Mitochondrial membrane depolarization and increased superoxide anion may contribute to the activation downstream effector caspases. Caspase inhibition leads to complete reversal of pterostilbene’s effect on cell viability. Further in vitro mechanistic studies and in vivo experiments are warranted to determine its potential for the treatment of breast cancer.

Fuente: J.A. Alosi et al., "Pterostilbene Inhibits Breast Cancer In Vitro Through Mitochondrial Depolarization and Induction of Caspase-Dependent Apoptosis", Journal of Surgical Research 161, 195–201 (2010)

... y también inhibe el cáncer del pulmón

Pterostilbene significantly decreased cell viability in lung cancer cells in a concentration- and time-dependent manner (P<0.001). Concentrations greater than 20 mM of pterostilbene produced significant growth inhibition by 72 h (P<0.001). Apoptosis and caspase-3/7 activity were significantly increased by pterostilbene treatment (P<0.05).

Fuente: J.G. Schneider et al. "Pterostilbene Inhibits Lung Cancer Through Induction of Apoptosis", Journal of Surgical Research 161, 18–22 (2010)